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Abstract— The growing demand for enantiomerically pure pharmaceuticals has impelled research on enzymes as catalysts for asymmetric 
synthetic transformations. However, the use of enzymes  for this purpose was rather limited until the discovery that enzymes can work in 
organic solvents. Since the advent of the PCR the number of available enzymes has been growing rapidly and the tailor-made biocatalysts 
are becoming a reality. Thus, it has been possible the use of enzymes for the synthesis of new innovative medicines such as carbohydrates 
and their incorporation to modern methods for drug development, such as combinatorial chemistry. Finally, the genomic research is 
allowing the manipulation of whole genomes opening the door to the combinatorial biosynthesis of compounds. In this review, our 
intention is to highlight the main landmarks that have led to transfer the chemical efficiency shown by the enzymes in the cell to the 
synthesis of bioactive molecules in the lab during the last 20 years.  © 2009 Elsevier Science. All rights reserved 
——— 
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“...I can forsee a time in which physiological chemistry will 
not only make greater use of natural enzymes but will 
actually resort to creating synthetic ones”. 
Emil Fischer, Nobel Lecture, 1902 
Introduction 
The advantages and disadvantages of the enzymes as 
catalysts in organic synthesis derived from their own 
nature. Enzymes catalyze reactions with remarkable rate 
accelerations over background (kcat/kuncat can reach 1017). 
They are chemoselective and regio- and stereospecific; 
however, usually present narrow substrate specificity 
limiting their application. Enzymes are environmental 
friendly catalysts since they work in aqueous solution and 
at moderate temperatures, but their poor stability under in 
vitro reaction conditions can become a strong limitation to 
their use in chemical synthesis. Many enzymes work under 
similar conditions of pH, temperature, etc., allowing 
combining them to perform several synthetic steps in one-
pot. In this manner, different problems related to the 
availability of substrates or product inhibitions may be 
overcome. 
Besides the unique properties of enzymes as catalysts, 
synthetic chemist have been reluctant to employ them for a 
number of reasons: 
i) most organic compounds are water-insoluble, and the 
water removal is tedious and expensive; 
ii) limited availability of biocatalysts with the desired 
activity and substrate specificity; 
iii) poor stability of the enzymes, and 
iv) relatively high cost of the biocatalyst. 
These drawbacks have been, at least partially, solved by the 
advances produced in the biocatalysis field over the last 20 
years. Thus, the finding that most enzymes can work in 
organic solvents1, have heightened the use of enzymes in 
organic synthesis. Recombinant DNA technologies and 
specially the PCR2, have facilitated obtaining new enzymes 
by a variety of approaches. Protein engineering by rational 
design3 or by in vitro evolution4 permits the modification of 
the enzyme substrate specificity, stability and other 
catalytic properties. Using the diversity offered by the 
immunological system, it has been possible to create tailor-
made enzyme active sites into antibodies by immunization 
with appropriate transition-state analogues5. The 
optimization of recombinant expression systems allows the 
application of efficient strategies for achieving high-level 
expression of both natural and engineered enzymes in 
different host cells, cutting down the cost of the biocatalyst6 
and expanding the array of reactions that can be afforded 
enzymatically. Finally, the use of immobilized enzymes 
present two main benefits i) easy separation of enzyme 
from the reaction mixture; and ii) the biocatalyst can be 
reused several times.7 
Several excellent comprehensive reviews on enzymes in 
organic synthesis have been published in the last years.8 In 
this review we will summarize the main landmarks that 
have led to enzymes be recognized as very useful catalyst 
in organic synthesis and especially in pharmaceutical 
processes where chirality is a key factor in the efficacy of 
many drugs and the work with multifunctional molecules is 
not unusual. 
General aspects of biocatalysis 
Enzymes in non-aqueous solvents 
For long time enzymes were believed to work efficiently 
only in aqueous solutions. Consequently, their utilization in 
organic synthesis was rather scarce since the low water 
solubility of many substrates represented a serious obstacle. 
This disadvantage, nevertheless, stimulated the search for 
systems based on the use of organic solvents in order to 
increase the solubility of hydrophobic substrates.9 The 
methods adopted evolved from the mixtures of water and 
water-miscible organic solvents, biphasic aqueous-organic 
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systems, reverse micellar systems, and finally in nearly 
anhydrous organic systems. Because the latter is attractive 
has undergone rapid expansion among the synthetic 
chemists during the last two decades.10 
In principle the replacement of water by an organic solvent 
should be adverse for the catalytic function of the enzyme, 
since water molecules are necessary to maintain the 
catalytically active conformation of the enzyme. However, 
the real question, as placed by Klibanov who did a leading 
research in the subject, should not be whether water is 
required but how much of it is necessary.1, 11 As long as the 
hydration shell required for retention of enzyme catalytic 
activity is preserved, the replacement of the rest of the 
water with an organic solvent should be possible without 
lose the active conformation. In general, the catalytic 
activity of enzymes in neat organic solvent is lower than in 
water. But this decrease in activity could be avoided and 
effective remedies are emerging.12 For example, the 
enzyme activity is usually higher in hydrophobic solvents 
than in the more hydrophilic, since the latter can strip the 
essential water from the enzyme molecule.13 The pH is one 
of the key factors for enzyme activity, but it has not 
meaning in organic solvents. Instead, in organic solvent 
media enzymes have "pH memory".14 In practice this "pH 
memory" can be achieved by dissolving the enzyme in 
water of optimal pH followed by freeze-drying or solvent 
precipitation prior to be used in an organic solvent. In this 
way the ionization state of the ionogenic groups of the 
enzyme are retained in the solid state and in organic 
solvent, which is also necessary for enzyme functioning.  
However, it has become important to know the effects of 
the surroundings of the enzyme molecules, in particular 
counter-ions and the structure of the solid catalyst particles, 
on the activity and selectivity of enzymes in low-water 
media.15 
Ionic liquids are a new class of non-aqueous solvents with 
non molecular, ionic character. These solvents are salts that 
are liquid at room temperature. Through the choice of 
cations and anions, the physical and chemical properties 
can be optimized for each application. The replacement of 
organic solvents by ionic liquids can lead to remarkable 
improvements regarding reactivity, selectivity and stability 
of the enzyme.16 For lipase catalyzed kinetic resolution of a 
racemate, it has been shown, that in most cases ionic 
liquids increase the enantioselectivity of the enzyme and 
improved conversion compared to organic media.17 
Enzyme immobilization 
The use of immobilized enzymes presents a number of 
technological advantages such as the possibility of reusing 
the biocatalyst and its easy separation from the reaction 
mixture. Exist a great variety of immobilization methods 
that can be grouped in several categories:7, 18 i) 
immobilization by entrapment; ii) non-covalent binding by 
adsorption on inert supports or by affinity immobilization; 
iii) enzyme crystallization; iv) covalent binding onto 
prefabricated carrier materials. 
Sometimes enzyme immobilization is used as synonym of 
enzyme stabilization. However, not all the immobilization 
methods improved the stability of the enzyme.19 Since 
enzyme immobilization means the restriction of the 
mobility of the enzyme, protein-protein interactions are 
greatly retard which diminishes inactivation caused by 
aggregation, adsorption on the surface of reaction vessels, 
dissociation of oligomeric proteins into subunits, and 
bimolecular processes of proteolysis. For a true 
stabilization of the enzyme it is necessary stabilize the 
three-dimensional structure of the protein. This effect is 
only possible to achieve with those immobilization 
methods that increase the rigidity of the protein.20 
From enzyme over-expression to tailor-made 
biocatalysts 
The PCR revolution and the biocatalysis. Much of the 
early work on biocatalysis focused on the use of readily 
available enzymes, such as esterases, proteases and lipases. 
Although these enzymes are still now largely being used 
for the asymmetric synthesis of pharmaceuticals, since the 
advent of PCR and the high-throughput technologies, the 
advances in the recombinant expression systems, and the 
genomic research, the array of enzymes available for 
organic synthesis is greatly expanding. This has made 
possible to carry out enzymatic reactions that otherwise are 
difficult to perform by chemical methods, like the synthesis 
or modification of complex molecules such as 
carbohydrates, asymmetric carbon-carbon bond formation, 
kinetic resolution of racemic epoxides or dioxigenation of 
aromatic compounds. 
The natural biodiversity is one of the main sources of new 
enzymes. Microorganisms living under extreme conditions 
of temperature, pH, salt concentration or pressure that are 
difficult or even impossible to be cultured, provide a large 
number of new enzymes. The new DNA techniques make 
possible to express enzymes from these organisms in others 
that can be cultured under controlled conditions such as 
Escherichia coli. Therefore, extremophilic microorganisms 
are providing biocatalysts able to work under conditions 
similar to those needed in organic synthesis.21 
Another source of new enzymes facilitated by the advances 
in recombinant DNA technologies, is the redesign of pre-
existing enzymes. Like the drug discovery process, the 
redesign of an enzyme can be afforded by rational or by 
non rational techniques. Rational redesign is usually 
restricted to those enzymes, which structure and 
mechanism are well known and understood. The 
improperly named non-rational methods are of general 
application since no previous information about the 
structure or mechanism of the enzyme is necessary. These 
methods try to reproduce in a lab-time scale the Darwinian 
scheme of natural evolution, consisting basically in: i) 
random genetic mutation; ii) gene recombination and iii) 
selection for higher fitness variants. 
Random and exhaustive mutagenesis can be achieved by 
several methods being the most popular the error-prone 
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PCR.22 Nature uses gene recombination to increase the 
variability produced by mutation. The first method for in 
vitro recombination of homologous genes was the DNA 
shuffling described by Stemmer (Fig. 1).23 Other methods 
developed for in vitro recombination include incremental 
truncation,24 staggered extension process25 and random-
priming recombination.26 The last step for the in vitro 
enzyme evolution, and the real bottleneck of this approach, 
is the identification of the evolved gene with the desired 
characteristics. The difficulty to find the best mutant in a 
library of 104-107 mutants is evident. The identification can 
be accomplished by screening or by selection.27 Genetic 
selection strategies can be applied when enzyme activity is 
essential for viability and growth. Screening requires to 
assay individually all the members of the library. Recent 
improvements in high-throughput screening allow to 
accomplish this task.28 
In vitro enzyme evolution has been successfully used to 
modify enzyme features that are of interest in organic 
synthesis, such as substrate specificity,29 optimum pH,30 
stereospecificity31 or enantioselectivity;32 this approach has 
also been utilized to improve the stability at high 
temperature33 or in organic solvents.34 A comprehensive list 
of evolved enzymes can be found in some recent reviews.35 
Catalytic antibodies: tailor-made biocatalysts. Besides 
the great diversity of enzymes, there are many important 
organic transformations for which do not exist any 
biocatalyst. For this reason, an old longing of the chemist is 
to create tailored biocatalysts. Basically speaking, enzyme 
catalysis is based on the stabilization of the transition-state. 
Thus, if the essential chemical and structural details of 
enzymatic catalysis are known, one should be able to 
design and build novel enzymes from scratch. Against the 
generally accepted concept that proteins with high affinity 
binding of stable ligands do not express catalytic activity, 
Jencks suggested at the end of the 60's, that stable 
molecules resembling the transition state of a reaction 
might be used as haptens to elicit antibodies with tailored 
catalytic activities and selectivities.36 Since the first reports 
Figure 1. In vitro molecular evolution process by DNA shuffling. This method involves the random fragmentation of homologous DNA sequences. After 
purification of a pool of small fragments, these are reassembled into a full-lenght gene in a PCR-like reaction without primers. Homologous sequences from 
different fragments hybridize and prime each other, and recombination occurs when fragment from one copy of a gene prime on another copy, causing a 
template switch. An additional PCR in presence of primers, typically yield a single PCR product of the correct size. Finally, the cloning of this PCR product 
lead to a combinatorial library of chimeric gene sequences produced by a variable number of crossovers. 
by the groups of Lerner37 and Schultz38 in the middle 80's, 
more than 100 reactions have now been successfully 
accelerated using catalytic antibodies (abzymes), including 
pericyclic processes, group transfer reactions, additions and 
eliminations, oxidations and reductions, aldol 
condensations, and miscellaneous cofactor-dependent 
transformations.39 
However, the catalytic efficiency of most catalytic 
antibodies generated to date is lower than that of their 
enzymatic counterparts. One major advance for the 
elicitation of antibodies with higher catalytic efficiencies 
has been the reactive immunization.40 Usually, haptens are 
designed to mimic the geometric and electronic features of 
the reaction transition state (Fig. 2).41 However, many 
enzymatic reactions proceed throughout a covalent 
complex between the enzyme and the substrate. In the 
reactive immunization, a reactive hapten is designed to 
promote a specific chemistry, such as the formation of a 
covalent bond, in the binding pocket of the antibody during  
6. New cycles of shuffling 
and screening (optional)
Shuffled library
2. Dennaturalization
and recombination
4. Second cycle of 
recombination and
extension
1. DNA fragmentation
5. Selection of best mutants
Library of
homologous genes
Novel shuffled genes
with desired properties
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Figure 2. The Claisen rearrangement of (–)-chorismate to form 
prephenate. The conformationally restricted endo-oxabicyclic dicarboxylic 
acid 1 mimics the structure of the transition state and was used as the 
template for generating antibodies with chorismate mutase activity.41 
its induction. In this way, the selection criterion is shifted 
from binding to catalysis. Using this approach, highly 
efficient catalytic antibodies with aldolase activity have 
been obtained (Fig. 3).42 The substrate specificity of these 
antibodies is broader than that observed with any natural 
aldolase and they are able to catalyze a wide variety of 
intermolecular aldol reactions between ketone-ketone, 
ketone-aldehyde, aldehyde-ketone and aldehyde-aldehyde, 
as well as several intramolecular aldol condensations.In 
order to find a highly efficient catalytic antibody, the 
screening of large libraries of antibodies is necessary. 
Several methods for screening antibody libraries for 
catalysis instead of binding have been developed. Catalytic 
enzyme-lined immunosorbent assay (catELISA)43 is, 
perhaps, the most widely used. An alternative approach is 
the chemical selection, in which catalytic antibodies are 
selected using a mechanism-based screening reagent. This 
method was demonstrated to select antibodies with 
glycosidase activity.44 
Figure 3. A) The 1,3 diketone 1 was designed to elicitate antibodies with 
aldolase activity. This hapten can both trap the requisite Lys residue in the 
antibody binding site (B) to then form the essential enamine intermediate 
and induce the appropiate binding sites for the two substrates. The 
aldehyde is represented by the 3-phenylpropiononyl portion of the hapten 
1.42 
Enzymes in the synthesis of chiral drugs 
Chirality plays a crucial role in nature and it is a key factor 
in the efficacy of many drugs.45 During the last two 
decades, the synthesis of enantiomerically pure compounds 
has emerged one of the most important fields of organic 
synthesis. For this purpose enzymes offer the possibility of 
performing highly stereoselective transformations under 
relatively mild reaction conditions avoiding the use of more 
extreme conditions that could cause problems with 
isomerization, racemization, epimerization, and 
rearrangement. 
Stereoselective transformations of chiral building blocks in 
the synthesis of antihypertensive, anticholesterol, anti-
Alzheimer, anti-inflammatory, and other pharmaceuticals 
have been previously reviewed.46 For achieving these 
transformations different classes of enzymes have been 
exploited. The most often used are: i) hydrolases (lipases, 
esterases proteases/amidases), for the synthesis of esters, 
acid, peptides/amides; ii) dehydrogenases, for the oxidation 
of alcohols and reduction of carbonyls;47 iii) mono- and 
dioxygenases for hydroxylation of unactivated carbon;48 iv) 
aldolases for the stereoselective condensation of carbonyl 
compounds; v) oxynitrile lyase for synthesis of chiral 
hydroxy nitriles.49 
Lipases have been the most popular biocatalysts in the 
synthesis of optically pure drugs. These enzymes are 
readily available commercially and work efficiently in 
organic solvents. This feature makes possible not only to 
solubilize substrates which are not soluble in water, also the 
desired enantioselectivity can be optimize by varying the 
solvent using a criterion of polarity and hydrophobicity.50 
However, when only one of the enantiomers is required, the 
enzymatic resolution of racemic substrates has the 
limitation that the maximum yield is 50 %. There are 
several ways to overcome this problem: i) the use of meso 
compounds or prochiral substrates; ii) stereoconversion of 
the remaining enantiomer; iii) dynamic kinetic resolution. 
In the latter case, the substrate is continuously isomerized 
during the resolution process. Dynamic kinetic resolution 
will lead to higher enantiomeric ratios of the products, 
provided that the rate of equilibration of the substrate 
enantiomers is about the same as, or higher than, the rate of 
removal of one enantiomer from the system.51 One can 
theoretically obtain 100% yield of one enantiomer. An 
illustrative example of this approach has been described by 
Bäckwall and co-workers.52 They showed that the 
isomerization of 1-phenylethyl alcohol (Fig. 4) by a 
ruthenium catalyst and enzymatic acylation with 4-
chlorophenyl acetate as acyl donor resulted in 
transformation of the racemic alcohol to enantiomerically 
pure acetate. In this example the ruthenium catalyst 
promotes the racemization of the alcohol substrate. 
Racemization involves abstraction of the α-proton to give a 
ketone intermediate and subsequent readdition of 
hydrogens to the ketone. In most cases reported, the 
reaction proceeded with > 99 % ee and in good yield. 
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Figure 4. Dynamic kinetic resolution of 1-phenylethyl alcohol.52 
Another alternative to kinetic resolution is parallel kinetic 
resolution of racemic mixtures.53 In this approach the 
slower reacting enantiomer is removed by a parallel 
reaction, ideally at an identical rate. Thus avoiding the 
decrease in the ee of the product at conversion values close 
to 50 %, due to the continuous increase of the relative 
concentration (and, therefore, the relative rate of reaction) 
of the less reactive substrate enantiomer. For instance, 
Mischitz and Faber studied the asymmetric nucleophilic 
opening of (±)-3-methyl-2-pentyloxirane (rac-1, Fig. 5) 
catalyzed by a crude immobilized enzyme preparation from 
Rhodococcus sp. (NOVO SP 409).54 The reaction in 
aqueous buffer gave the diol (S)-2 in only 40% ee. 
However, when the enzymatic hydrolysis of (±)-1  was 
carried out in the presence of the non-natural nucleophile 
azide, the (S)-diol, 2, and  (R)-azidoalcohol, 3, were 
obtained in >90% and 60% ee respectively (Fig. 5). 
Therefore, a simultaneous and opposite enantio-
discrimination of  two nucleophiles (water and azide) was 
observed. This parallel kinetic resolution afforded the (S)-
diol product in higher ee. 
Figure 5. Simultaneous asymmetric hydrolysis and azidolysis of (±)-2-
methyl-2-pentyloxirane.54 
Enzymatic synthesis of carbohydrates: new tools for 
new drugs 
Traditionally, carbohydrates were associated with structural 
functions and energy storage. Development of 
glycobiology and glycochemistry during the past two 
decades has revealed that carbohydrates are involved in a 
broad range of biological functions, mainly related to cell 
recognition events.55 Many of these events occur at the very 
early stage of disease development and other signaling 
processes. Control of such recognition processes has 
become an important target for new drug development. 
Carbohydrates have multiple hydroxyl functions of similar 
chemical reactivity; for example, five monosaccharides can 
be linked together to form linear or branched chains that 
can give rise to 32 million different compounds.56 
Therefore, a special knowledge of selective reactions and 
protecting groups are needed to achieve successfully their 
synthesis and modification. Because of that, it is in the field 
of carbohydrate chemistry where the enzymatic 
transformations has made a biggest impact during the last 
years.  
Aldolase enzymes for C—C bond formation 
Aldolases have attracted the interest of organic chemists 
because their ability to catalyze the formation of C—C 
bonds by an aldol addition reaction between an aldehyde 
and a ketone, with a high degree of stereochemical control. 
In general, they show a very strict specificity for the donor 
substrate (the ketone), but tolerate a broad range of 
acceptor substrates (the aldehyde). 
Figure 6. The four DHAP-dependent aldolases are stereocomplementary, 
allowing the synthesis of the four possible diaestereoisomers for a given 
pair of substrates. 
Dihydroxyacetone phosphate (DHAP) dependent aldolases 
produce 2-keto-3,4-dihydroxy adducts and, with some 
exceptions,57 they control the configuration of the newly 
formed stereogenic centers. An additional advantage of 
these enzymes is that they are stereocomplementary, that is, 
their use allows the synthesis of the four possible 
diaestereoisomers for a given pair of substrates (Fig. 6). 
DHAP-dependent aldolases have shown their utility in the 
synthesis of carbohydrate, carbohydrate-like structures or 
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non-carbohydrate compounds. A comprehensive 
description can be found in several excellent reviews58 and 
references therein. 
Pyruvate or phosphoenol pyruvate (PEP) dependent 
aldolases yield 3-deoxy-2-keto acids. In vivo, pyruvate-
dependent aldolases have a catabolic function meanwhile 
the PEP-dependent aldolases are involved in the 
biosynthesis of keto acids. These aldolases provided 
adducts that are not only densely but also differentially 
functionalized.59 Thus, four different state of carbon 
oxidation can be found in four contiguous carbons. This 
substitution pattern allows transformation of aldol adducts 
to a variety of complex natural products (Fig. 7). 
Figure 7. PEP-dependent aldolases provide adducts with four different 
state of carbon oxidation, allowing their transformation to a variety of 
complex natural products.59 
2-deoxyribose-5-phosphate aldolase (DERA) catalyzes the 
aldolic condensation between acetaldehyde and D-
glyceraldehyde-3-phospate and determines the S 
configuration of the newly formed stereogenic center.60 
Beside acetaldehyde this enzyme is able to accept propanal, 
acetone and fluoroacetone as donor substrates.60b DERA it 
is the only aldolase able to accept two aldehydes as 
substrates, allowing sequential two- or three-substrates 
aldol reactions.61 The unnaturall pyranose obtained after 
DERA-catalyzed addition of acetaldehyde as donor are 
useful synthons for the synthesis of natural products as it 
has been illustrated by the concise total synthesis of 
epothilones A and C.62  
Glycine dependent aldolases produce β-hydroxy-α-amino 
acids that are medicines by themselves or can be used as 
chiral building blocks for the production of drugs.63 Their 
use in synthesis is hampered because the poor 
stereoselectivity that often leads to mixtures of erythro and 
threo compounds.63 Despite of this limitations, L-threonine 
aldolase and D-threonine aldolase have been used for the 
synthesis of several β-hydroxy-α-amino acids on a 
preparative scale.64 L-Threonine aldolase has been also used 
for the synthesis of potent sialyl Lex mimetics65 and the 
immunosuppressant mycestericin D.66 
From glycosidases to glycosynthases. 
Glycosidases are readly available enzymes and use simple 
glycosyl donors, that can be even the free monosacharide. 
These hydrolytic enzymes are able to catalyze the 
formation of glycosidic bonds in a stereospecific manner.67 
However, when applied to the synthesis of di- and 
oligosaccharides the problem of the regioselectivity has to 
be faced. In contrast to lipase and protease that work in 
anhydrous organic solvents, glycosidases do not do it. 
Therefore, when using for synthesis of glycosides the 
hydrolysis is always a competitive reaction. 
Several tricks have been applied to improve yield and to 
control the regioselectivity of glycosidase-catalyzed 
reactions:68 
i) Use of glycosyl donors very reactive, in such a way that 
it is cleaved more rapidly than the product formed. Under 
these conditions, the reaction is kinetically controlled. 
ii) Introduction of subtituents at certain positions in the 
sugar acceptor. For instance, it has been shown that both 
the nature of the substituent and the anomeric configuration 
influence the regioselectivity and the yield of the 
glycosidation.69 
iii) Manipulation of the medium, using organic cosolvents 
to reduce the total volume of water. Also, addition of salts 
at high concentration has been used in order to reduce the 
water activity. The use of lipid-coated glycosidases 
improves the behavior of the enzyme in media with low 
water activity.70 
Figure 8. Proposed mechanism of glycosynthases. The enzyme-derived 
nucleophilic carboxylate (R’’) has been mutated to glycine, serine or 
alanine.71 
An alternative approach is the use of specifically mutated 
glycosidase (named glycosynthase), which can efficiently 
synthesize oligosaccharides, but does not hydrolyze them.71 
For the case of glycosynthases, an active carboxylate 
nucleophile in the catalytic center of the enzyme is replaced 
with a nonnucleophilic amino acid side chain, resulting in 
an enzyme which is catalytically inactive since it cannot 
form the glycosyl-enzyme intermediate (Fig. 8). However, 
the mutant enzyme can transfer an activated glycosyl 
derivative, bound at the active site in the place of the 
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Figure 9. Three strategies for the chemo-enzymatic synthesis of homogeneous glycoproteins. A) Use of endoglycosidases for the exchange of sugar chains;78 
B) combined use of endoglycosidases, glycosyltransferases and proteases for the synthesis of a homogeneous glycoforms;77 C) glycoprotein synthesis 
mediated by inteins.79
normal glycosyl-enzyme intermediate, to a suitable 
acceptor bound in the aglycon pocket. Glycosyl-fluorides72 
are appropriate activated glycosyl donors since they are 
readily synthesized and have a small leaving group. As the 
disaccharide products are not hydrolyzed this method 
provide a high-yielding synthetic procedure of 
oligosaccharides. A similar approach has been used to 
obtain glycosynthases from endo-glucanases.73 
Glycosyltransferases: one enzyme-one linkage. 
Glycosyltransferases in vivo are responsible for the final 
“decoration” of proteins and lipids and contributes to the 
great variety and complexity of secondary metabolites in 
plants, bacteria and other organisms. Their strict control 
over the stereo- and regioselectivity of the newly formed 
glycosidic bond, have led to the “one enzyme-one linkage” 
concept.74 
The synthetic utility of glycosyltransferases has been 
demonstrated in the synthesis of numerous complex 
oligosaccharides and glycoconjugates.75 
Enzymes have allowed affording the in vitro synthesis of 
homogeneus glycoproteins, a difficult task to obtain by in 
vivo methodologies since glycosylation is a 
posttranscriptional modification and it is affected by 
several environmental factors.76 Several strategies have 
been developed in the last years for the enzymatic synthesis 
of glycoproteins (Fig. 9). The combined use of 
endoglycosidases, glycosyltransferases and proteases has 
been applied to the synthesis of a homogeneous RNase B 
glycoform.77 The use of endoglycosidases A or M allows 
the exchange of sugar chains to obtain a protein with 
homogeneous N-linked glycans.78 Finally, other approach 
makes use of a natural protein-splicing mechanism 
mediated by inteins.79  
In spite of all these impressive examples, the use of 
glycosyltransferases in synthesis faces two majors 
drawbacks: i) their limited availability and ii) the need of a 
nucleotide activated sugar as donor. 
i) Historically, most glycosyltransferases studied have been 
from mammalian sources because these have been the 
focus of glycobiology and bio-medical studies. Interest is 
increasing in bacterial glycosyltransferases. Many bacterial 
glycosyltransferases are able to produce mammalian-like 
structures and, in addition, in microorganisms it is possible 
to find transferases with specificities not yet found in 
mammalian enzymes.80 An additional advantage of 
bacterial glycosyltransferases is that usually show broader 
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substrate specificity than their mammal counterpart.81 Work 
in our lab on recombinant α 1,6-fucosyltransferase from 
Rhizobium sp.82 has shown that this enzyme is able to 
accommodate a variety of modifications on the acceptor 
substrate. Thus, it is able to accept as substrate, oligomers 
and monomer of GlcNAc and it does not seem to present 
selectivity for the anomeric configuration of the acceptor. 
ii) The sugar-nucleotide used by glycosyltransferases as 
donor, is too expensive to be used in stoichiometric amount 
in medium or large-scale synthesis but, even more 
important, the nucleoside phosphate released during the 
reaction is a natural inhibitor of glycosyltransferases. This 
problem can be avoided removing the nucleotide with 
alkaline phosphatase83 or, in a more sofisticated way, by in 
situ regeneration of the glycosil donor. The ability of most 
of the enzymes to work under similar conditions of pH and 
temperature together with their high specificity for 
substrate, allows the combination of several enzymes, each 
with different catalytic activities, in the same reaction flask. 
These properties are the basis of the strategy developed by 
Whitesides and co-workers in 198284 for the synthesis of N-
acetyllactosamine with in situ regeneration of UDP-Gal. 
Afterwards, other recycling systems for several sugar-
nucleotide have been developed.85 The use of bifuctional 
fused enzymes86 and “superbeads” containing the necessary 
enzymes for the regeneration of the sugar-nucleotide co-
immobilized on Ni-agarose,87 are recent improvements to 
the traditional scheme for in situ sugar-nucleotide 
regeneration cycle. 
In an analogue way, multienzyme systems have been 
developed for regeneration of other cofactors. Because the 
interest of bioactive oligosaccharides sulfates, the methods 
for the recycling of 3’-phosphoadenosine 5’-phosphosulfate 
(PAPS), are noteworthy.88 
Enzymes enter the field of combinatorial chemistry 
In the early 90’s, combinatorial chemistry revolutionized 
the drug discovery field changing the traditional rational 
drug design approach for the idea of covering a vast range 
of chemical diversity where a “hit” could be found faster.89 
A more recent approach in combinatorial chemistry is to 
create smaller and focuses libraries. Thus, combinatorial 
chemistry is used to generate a high degree of structural 
and chemical diversity on initial lead compounds in order 
to optimized them for binding, target specificity, 
bioavailability, etc. Biocatalysts have been recently 
incorporated to the array of synthetic tools for 
combinatorial chemistry with special emphasis on focuses 
libraries. Biocatalysts can be employed in two different 
combinatorial schemes to generate libraries of compounds: 
i) combinatorial biocatalysis, which assembles in vitro new 
compounds and derivatives using isolated enzymes and ii) 
combinatorial biosynthesis, which shuffled or modified the 
genes of natural biosynthetic pathways to produce in vivo 
libraries of ‘unnatural’ natural products. 
Enzymes in polymer-support synthesis 
Combinatorial chemistry often involves the synthesis on 
polymer supports. The advantage of this synthetic 
methodology mainly stems from the ease work-up of 
reactions, which allows the automatization of the process. 
In polymer-support synthesis the substrate is anchored to 
the polymer through a functional group, the so-called 
linker, which must be stable during the synthesis and has to 
be cleavable at the end of the synthetic route with high 
selectivity. Under the mild conditions where enzyme works 
most of compounds are stable and therefore, the use of 
enzymes has open up alternative opportunities to release 
Figure10. Principle for the development of the enzyme-labile 4-
acyloxybenzyloxy linker group.91 
compounds from polymeric supports. Enzyme-labile 
linkers have been developed, involving the use of 
hydrolases such as protease, lipase or acylase.90 For 
instance, Waldmann et al. described the exo-linker 1, which 
comprises a 4-acyloxy-3-carboxy-benzyloxy group (Fig. 
10).91 The linker 1 is attached as an amide to the solid 
phase. It contains an acyl group, for example acetate, which 
can be cleaved by lipases or estereases. Cleavage of the 
acyl group by a lipase generated a phenolate 2, which 
fragments to give a quinone methide 3 and releases the 
desired product 4. The quinone remains attached to the 
solid phase and is trapped by water or an additional 
nucleophile. 
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Figure11. General strategy for the liquid-phase synthesis of disaccharides using glycosidases.96a  
Enzymes can also be exploited as efficient and selective 
catalyst in solid-phase synthesis where conventional 
chemistry is laborious and difficult. Wong et al. reported 
the synthesis of sialyl Lewisx glycopeptide on a solid 
support by the use of glycosyltransferases.92 In addition, 
the target product was detached from the solid support 
through a protease-catalyzed hydrolysis. After this work, 
several syntheses of oligosacharides on solid support93 or 
on soluble polymeric support94 have been reported. Solid-
phase and liquid-phase synthesis of glycopeptides, 
glycolipids, oligonucleotides and oligosaccharides have 
been reviewed by Zehavi.95 
In a different approach using soluble monomethylether of 
polyethyleneglycol as support, glycosidases have been 
used for both glycosidation of a sugar acceptor and for 
removal of the unreacted monosaccharide acceptor.96 As 
shown in Fig. 11, the glucose anchored to the soluble 
support is galactosylated using β-galactosidase. Then, the 
unreacted monosaccharide glucose was removed by the 
combined use of α- and β-glucosidases to obtained only 
MPEG-bounded disaccharides. Finally, disaccharides 
were released from the polymer by cleavage of the 
linker.96a 
Recently, Flitsch et al.97 reported the first example of 
protease-catalyzed high-yielding peptide synthesis on 
solid support in bulk aqueous buffer, with no need for 
organic cosolvent or activated carboxylic acid. 
These and other many examples of solid and liquid-phase 
biocatalytic synthesis show that the biocatalytic synthetic 
machinery is ready to be used for the preparation of 
compound libraries. 
Combinatorial Biocatalysis 
The creation of focused libraries is based on 
derivatization of existing molecules. This approach 
mimics the chemistry that occurs in biological systems 
where precursors are modified by the action of 
biocatalysts. For modification of existing lead 
compounds, the special properties of enzyme as catalysts 
report some advantages over synthetic chemical 
reactions:98 
i) The high chemo-selectivity of enzymatic reactions 
allows modifying only one kind of functional groups in a 
scaffold molecule that typically contains several different 
functional groups. 
ii) The enzyme regioselectivity provide the opportunity 
for specific combinatorial modification of lead molecules 
with multiple copies of the same functional group, e.g. 
glycosylation catalyzed by glycosyltransferases with 
different regioselectivity. 
iii) The enzyme stereocontrol over the reaction permit a 
combinatorial approach to the three-dimensional structure 
of the compound, e.g. using the four DHAP-dependent 
aldolases.58b 
A myriad of biocatalytic reactions are available for 
combinatorial biocatalysis (Table 1). These reactions can 
be grouped in three mayor categories:98a i) introduction of 
new fuctional groups; ii) modification of existing 
functionalities and iii) addition onto functional groups. 
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Table 1. Enzyme catalyzed reactions with application to combinatorial biocatalysis.98a 
Introduction of new functional groups Modification of existing functional groups Addition onto functional groups 
Carbon-carbon bond formation 
Hydroxylation 
Hydrogenation 
Halogenation 
Peroxidation 
Epoxidation 
Cycloadditions 
Halohydrin formation 
Addition of amines 
Oxidation of alcohols to aldehydes and ketones 
Reduction of aldehydes and ketones to alcohols 
Oxidation of sulfides to sulfoxides 
Oxidation of amino groups to nitro groups 
Oxidation of thiols to thioaldehydes 
Hydrolysis of nitriles to amides and carboxilic 
acids 
Replacements of amino groups with hydroxyl 
groups 
Lactonization 
Isomerization 
Epimerization 
Dealkylation 
Methyl transfer 
Acylation 
vynil esters 
trihaloethyl esters 
vinyl carbonates 
vinyl carbamates 
oxime esters 
oxime carbonates 
bifunctional esters 
Glycosylation 
glycosides 
aminoglycosides 
glycosilic acids 
Amidation 
amides 
peptides 
hydrazides 
Phosphorylation 
phosphates 
phospholipids 
An important issue regarding combinatorial bicatalysis is 
that of orthogonality.99 Modification of a substrate by one 
enzyme, 'A', may prevent it from being substrate for 
another enzyme, 'B', while the modification of the initial 
substrate by 'B', may not preclude it from being a 
substrate for the first enzyme, 'A' (Fig. 12). The reactions 
are performed iteratively. A first generation of derivatives 
is modified by another round of biocatalytic reactions at 
additional reactive sites to produce a second generation of 
derivatives. After several iterations is possible to create a 
great number of derivatives from the original lead 
compound (Fig. 13).  
Figure 12. Orthogonality of biocatalysts.99 
Although combinatorial biocatalysis is an emerging 
technology in the field of drug discovery, published 
application have expanded at a growing rate. New 
advances including iterative derivatization of small 
molecules and complex natural products, regioselectively 
controlled libraries, novel one-pot library synthesis, etc., 
have been recently reviewed.100 
Let the cell to make the chemistry: from metabolic 
engineering to combinatorial biosynthesis. 
Fermentation processes is a traditional approach of the 
pharmaceutical industry for obtaining natural-bioactive 
products. The possibility to manipulate metabolic 
pathways at genetic level has opened the door to use the 
cell like a chemical factory for the production of new 
‘unnatural’ natural products. The whole-cell approach is 
especially appealing to obtain compounds produced by 
the consecutive action of several enzymes or when co-
factor regeneration is required.  
The cell factory: an alternative strategy for the 
synthesis of oligosaccharides. Recombinant whole-cells 
over-expressing glycosyltransferases, have been used as 
biocatalyst for the synthesis of oligosaccharides101 in a 
similar way that is done with the isolated enzymes. That 
is, the sugar-nucleotide donor and the corresponding 
acceptor are incubated in the presence of the recombinant 
cells. The concept of cell factory implies the use of the 
cell metabolic machinery —natural or engineered— for 
the production of the desired compound from simple and 
inexpensive substrates. 
Thus, E. coli cells transformed with a plasmid codifying 
for the enzymes to recycle UDP-Gal —sucrose synthase 
and UDP-galactose-4-epimerase102— and different 
galactosyltransferases have been used as a galactoside-
producing factory.103 
A
Enzyme A
B
Enzyme B
A
B
Enzyme B
Enzyme A
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Figure 13. Iterative synthesis of a 600-member library from the flavonoid bergenin.98b  
Endo and co-workers have developed an alternative 
approach for the large-scale production of sugar-
nucleotides and oligosaccharides through coupling of 
engineered bacteria.104 This system is based in the 
combined use of Corynebacterium ammoniagenes, a 
bacterium able to produce UTP from inexpensive orotic 
acid, with E. coli strains metabolically engineered with the 
different sugar-nucleotide biosynthetic genes. Therefore, E. 
coli cells expressing galactose-1-phosphate 
uridyltransferase, galactokinase, glucose-1-phosphate 
uridyltransferase and pyrophosphatase, coupled with C. 
ammoniages cells were able to accumulate 44 g/L of UDP-
Gal in the culture supernatant after a 21 h. reaction (Fig. 
14A).105 In a similar way, system for the production of 
other sugar-nucleotides like UDP-glucose, UDP-N-
acetylglucosamine,106 GDP-mannose, GDP-fucose107 and 
CMP-neuraminic acid108 have been developed. For this last 
system, two recombinant E. coli strains were used; one 
expressing the CTP synthase and the other expresses the 
CMP-NeuAc synthase (Fig. 14B). 
When these sugar-nucleotide production systems are 
coupled with a new strain of E. coli over-expressing a 
glycosyltransferase, different oligosaccharides can be 
efficiently produced (Fig. 14).105, 107-109 
Combinatorial biosynthesis: creating new polyketides. 
Polyketides belongs to a very important family of 
compound for the pharmaceutical industry. Nowadays, 
more than 40 polyketide drugs are in the market including 
antibiotics, immunosuppresants, antifungals and cancer 
chemotherapeutics.110Production of new polyketides is 
probably the best example showing the advanced 
application of combinatorial biosynthesis, which has been 
facilitated by the modular structure of polyketide synthases 
(PKSs). PKSs complex catalyzes the assembly of specific 
types of polyketides from simple carboxylic acids.111 The 
synthesis begins when the starter substrate is loaded in the 
acyl carrier protein (ACP) as a thiol ester. Then, the acyl 
moiety is transferred to β-ketoacyl:ACP synthase (KS) 
domain leading to a two-carbon atoms increase of the chain  
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Figure 14. Production of sugar-nucleotides and oligosaccharides by combined use of C. ammoniagenes with E. coli strains metabolically engineered. A) 
Production system for UDP-Gal and globotriose.105 B) Production system for CMP-NeuAc and 3’-sialyllactose.108 
length. This is followed by successive two carbon 
extensions in a new ACP. Eventually, the polyketide is 
completely synthesized and, then, released by the activity 
of a specific thioester (TE) domain (Fig. 15). 
PKSs control the selection of the starter substrate, the 
length of the chain, the reduction degree and the 
stereochemistry of the newly formed chiral centres.112 
Thus, inactivating, altering the order of the genes in the 
PKS biosynthesis pathway or exchanging genes from 
different organisms, novel hybrid polyketides can be 
obtained (Fig. 16).113 However, the design of new 
polyketides must face some dificulties. After being released 
from the PKSs, the polyketide must be cycled by non-PKS 
enzymes and heterologous cyclases may not work properly 
on the ‘unnatural’ linear intermediate, which results in the 
formation of incorrectly cyclized products.114 Also, the 
ACPs are not always interchangeable.114a Nevertheless, this 
approach has provided a large number of novel 
compounds.115 
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Figure 15. The erythromycin PKS system. The pathway has three PKS polypeptides containing six modules and loading and releasing domains. The 
cyclized structure shown need to be further modified to bring erythromycin to its final structure. 
The final enzymatic trimming with carbohydrates, methyl 
groups, etc., gives even more structural diversity to the 
resulting aromatic compounds than the PKS. The 
importance of the sugar moiety in the biological activity of 
these compounds has led to the idea of using combinatorial 
biosynthesis to modify the glycosylation pattern of the 
aglycon.116 The richest group of sugars present on many 
polyketides is the 6-deoxyhexoses. A great number of 
genes involved on the biosynthesis of these carbohydrates 
have been already identified and isolated.117 Many of the 
glycosyltransferases involved in the biosynthesis of 
secondary metabolites are known to possess relaxed 
specificity for the sugar moiety and the aglycon.118 
Valuable hybrid pharmacological compounds such as 
antibiotics can be made by combinatorial biosynthesis with 
bacterial deoxysugar biosynthesis genes. One approach is 
to introduce heterologous genes into a mutant strain 
blocked in the biosynthesis of its own deoxysugar.119 These 
recombinant strains can synthesize novel sugar derivatives 
through the combined action of the host genes and the 
incorporated genes. Another approach to incorporate 
different sugars in the aglycon is to exchange 
glycosyltransferase genes between species producing 
structurally related bioactive compounds.120 
Conclusions 
Medicinal chemistry has decisively contributed to the 
welfare of the humankind during the last century. 
Nowadays, the apparition of new diseases, the rising of 
antibiotic-resistant pathogenic bacteria, the increasing 
consciousness of the variable activity of different optical 
isomers, the search for higher selectivity and less toxicity, 
the individualization of the medicine in the post-genomic 
era, etc., are new challenges that pharmaceuticals research 
must face. In this new landscape, the exciting advances in 
the biocatalysis field during the past years have placed this 
technology in position to play an important role in the drug 
discovery process. 
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Figure 16. Two different strategies for the synthesis of “unnatural” natural products by combinatorial biosynthesis. A) Precursor-directed polyketide 
biosynthesis; inactivation of the first ketosynthase (KS) prevent the production of the second-step precursor, allowing to prime the second module with 
synthetic analogues of the product of the first module.113a B) Introduction of auxiliary catalytic domains; by replacing the ketoreductase (KR) domain of 
module 2 with a KR-DH(dehydratase)-ER(enoylreductase) tridomain from the rapamycin synthase ( ) new chemistry is introduced into the reaction 
sequence catalysed by the module.113c  
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